Latest From Biotech Now

Why State Food Labeling Mandates Are Bad For Consumers and Farmers

Coalition for Safe Affordable Food

Hundreds of food and agri-business representatives are in Washington this week visiting with members of the Senate to talk about biotechnology, GMOs, and food labels.  Bob Stallman, president of the American Farm Bureau Federation, explains in The Hill why the Senate needs to act soon to pass a federal GMO food labeling bill: There is a growing anxiety among American farmers, manufacturers and shoppers about confusing and expensive changes coming soon to store shelves unless Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

WSJ Article Cherry Picks Cost, Ignores Value of Medicines

Jim Greenwood

Today’s Wall Street Journal story, “Price Increases Drive Drug Firms’ Revenue” reaffirms that old chestnut, “…a little information is a dangerous thing…”  When speaking to the complexities of the costs and benefits of America’s healthcare system, a publication like the Wall Street Journal should not cherry pick one aspect of that system to cover while ignoring the rest. Unfortunately and uncharacteristically, in this case, the paper focused on particular costs while ignoring value. In fact, Read More >

Health  |  Leave a comment  |  Email This Post
Tags: ,

5 Tips for a BIO 2016 Session Proposal: Help us Imagine the Future

2016 BIO International Convention

As you hopefully know we have an open call for session ideas and proposals for BIO 2016, and it closes next week, Thursday, October 15. Every year, the education team here at BIO receives numerous inquiries from prospective submitters on what they can do to solidify their spot on the BIO International Convention program. Unfortunately there is no simple answer – not even seeking advice from a psychic will guarantee your place. BIO receives hundreds of Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,

Biopharma Companies Fight Tropical Diseases to Improve Global Health


Neglected tropical diseases (NTDs) are a group of devastating viral, bacterial, and parasitic diseases that predominantly burden individuals and communities living in poverty. NTDs received the moniker “neglected” due to the lack of attention they have received from the global biopharmaceutical community, and the resultant dearth of products available to prevent, diagnose, and treat them. This has been changing, though – Knight Therapeutics Inc. developed a drug to treat leishmaniasis (Impavido®) in 2014, Sanofi Pasteur Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Biomarkets: Looking For The Hole In The Donut

synthetic biology

This piece by Allan L. Shaw was originally published in Life Science Leader. The biopharma sector has enjoyed increased market success over the last few years. And while some may be tempted to bask in the optimistic “bio-euphoria,” others question whether the industry might be in the midst of a market bubble. What led to this current period of biopharma success, despite the industry’s inherent risks (e.g. scientific, clinical, regulatory, and commercial)? Several factors contributed Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,